Eye drug Eylea took in $400 mln at end of 2013 -Regeneron CEO

Jan 14 (Reuters) - Regeneron Pharmaceuticals Inc. will report about $400 million in U.S. sales of its high-profile eye drug Eylea for the fourth quarter of 2013, bringing the total for the year to about $1.4 billion, the U.S. biotech company's chief executive said on Tuesday.

from Reuters: Company News http://feeds.reuters.com/~r/reuters/companyNews/~3/Iqj_1ndVu10/story01.htm

via IFTTT